Table 1.
Characteristics and quality assessment of the included studies
| Reference (year) | Country | Design | Period | No. of patients | Age (year) | Gender (F/M) | Neoadjuvant therapy (pre-operative) | Interested outcomes | Study quality | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| Chemoradiotherapy | Radiotherapy | ||||||||||
|
| |||||||||||
| ELAPE/APEE | ELAPE/APE | ELAPE | APE | ELAPE/APE | ELAPE/APE | ||||||
| Barker. et al. 2012 | UK | N-RCT | 2004-2011 | 12/9 | 69/70 | 5/7 | 3/6 | 1/8 | 2/0 | 3, 4 | ******** |
| D. Asplund. et al. 2011 | Sweden | N-RCT | 2004-2009 | 79/79 | 67/68 | 35/44 | 24/55 | 15/5 | 60/66 | 1, 2, 3, 4 | ******* |
| Han. et al. 2012 | China | RCT | 2008-2010 | 35/32 | 63/68 | 15/20 | 11/22 | 10/9 | 1, 2, 3, 4 | ******* | |
| Mattias Prytz et al. 2014 | Sweden | N-RCT | 2007-2009 | 518/209 | 68/71 | 209/309 | 93/116 | 159/32 | 456/144 | 1, 2, 4 | ******** |
| N. P. West. et al. 2009 | UK | N-RCT | 1997-2008 | 176/124 | 66/68 | 54/116 | 37/87 | 84/48 | 130/90 | 1, 2, 4 | ***** |
| P. G. Vaughan-Shaw. et al. 2012 | UK | N-RCT | 2009-2011 | 16/20 | 71/72 | 9/7 | 7/13 | 9/7 | 7/9 | 1, 2, 3, 4 | ******** |
| S. K. perdawood et al. 2014 | Denmark | N-RCT | 2006-2012 | 68/39 | 68/69 | 23/45 | 12/27 | 58/19 | 1, 2, 3, 4 | ******** | |
| Stelzner. et al. 2011 | German | N-RCT | 1997-2010 | 28/46 | 66/64 | 9/19 | 9/37 | Data not available | 1, 2, 4 | ******* | |
| Zhangxin. et al. 2014 | China | N-RCT | 2011-2013 | 33/28 | 58/62 | 15/18 | 14/14 | Data not available | 2, 4 | ****** | |
| Martijnse. et al. 2011 | UK | N-RCT | 2000-2010 | 134/112 | 63/62 | 15/18 | All underwent | 1, 2, 3 | ***** | ||
1: CRM; 2: IOP; 3: LR; 4: Wound complication; RCT: Randomized Controlled Trial; N-RCT: Not Randomized Controlled Trial.